AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ORTHOCELL LTD

0.940

-0.040-4.08%

Volume:412.39K

Turnover:388.43K

Market Cap:254.82M

PE:-24.50

High:0.980

Open:0.980

Low:0.920

Close:0.980

52wk High:1.700

52wk Low:0.855

Shares:271.09M

Float Shares:194.08M

Volume Ratio:1.16

T/O Rate:0.21%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.038

EPS(LYR):-0.038

ROE:-89.70%

ROA:-26.42%

PB:17.49

PE(LYR):-24.50

Loading ...

Overview Company News Filings

Orthocell Eyes Fiscal 2027 Entry Into UK, European Union Markets

MT Newswires Live

BRIEF-Orthocell Posts Quarterly Revenue Of A$3.2 Million

Orthocell Finalizes Agreement With Biotechnology Company

MT Newswires Live

BRIEF-Orthocell Finalises Strategic Investment In Marine Biomedica

Orthocell Ltd - Orthocell Finalises Strategic Investment in Marine Biomedica

THOMSON REUTERS

Orthocell Ltd - Co Increased Its Equity Interest in Marine Biomedical to 11.7% for Total Investment of AU$1.05 Million

THOMSON REUTERS

BRIEF-Orthocell Posts A$3.2 Million In Revenue For Quarter Ended 31 December

Orthocell Posts 45% Revenue Growth for December 2025 Quarter

MT Newswires Live

Orthocell Ltd - Revenue a$3.2 Mln for Quarter Ended 31 December

THOMSON REUTERS

Orthocell Sells 100 Units of Nerve Repair Product in US

MT Newswires Live

Canaccord Genuity Starts Orthocell at Speculative Buy with AU$1.33 Price Target

MT Newswires Live

Orthocell Submits Application to the British Standards Institution for Approval for Commercial Distribution of Nerve Repair Product, Shares Up 3%

MT Newswires Live

BRIEF-Orthocell Submits Regulatory Application For Commercial Distribution Of Remplir

Orthocell Ltd - Submits Regulatory Application for Commercial Distribution of Remplir Into EU + UK Nerve Repair Market

THOMSON REUTERS

XRP price slowly forms a bullish pattern amid good Ripple news

Ripple CTO Shares Hilarious Moment With Chris Larsen at Key Event: Details

Ripple CEO Reacts to Bank Charter Approval, Slams Banking Lobby

Canadian analysts project increased XRP adoption in fintech sector

Orthocell Sells Nerve Repair Product in Hong Kong

MT Newswires Live

Remplir™ Nerve Sparing Prostate Cancer Surgery Commercial Opportunity Gathers Momentum with ~100 Surgeries Now Performed with Multiple Surgeons Nationwide

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/OCC.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"OCC.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"OCC.AU\",,,,,undefined,":{"symbol":"OCC.AU","market":"AU","secType":"STK","nameCN":"ORTHOCELL LTD","latestPrice":0.94,"timestamp":1770873120000,"preClose":0.98,"halted":0,"volume":412391,"delay":0,"changeRate":-0.04081632653061228,"nameEN":"ORTHOCELL LTD","floatShares":194076512,"shares":271090199,"eps":-0.03837,"marketStatus":"Closed","change":-0.04,"latestTime":"02-12 16:12:00 AEDT","open":0.98,"high":0.98,"low":0.92,"amount":388432,"amplitude":0.061224,"askPrice":0.94,"askSize":31819,"bidPrice":0.925,"bidSize":8000,"shortable":3,"etf":0,"ttmEps":-0.03837,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1770937200000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":0.98,"openAndCloseTimeList":[[1770850800000,1770872400000]],"volumeRatio":1.16003,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"OCC.AU\",,,,,undefined,":{"symbol":"OCC.AU","floatShares":194076512,"roa":"-26.42%","roe":"-89.70%","lyrEps":-0.03837,"volumeRatio":1.16003,"shares":271090199,"dividePrice":0,"high":0.98,"amplitude":0.061224,"preClose":0.98,"low":0.92,"week52Low":0.855,"pbRate":"17.49","psRate":"33.75","week52High":1.7,"institutionHeld":0,"latestPrice":0.94,"committee":-0.598182,"eps":-0.03837,"divideRate":0,"volume":412391,"delay":0,"ttmEps":-0.03837,"open":0.98,"prevYearClose":1.085,"prevWeekClose":0.91,"prevMonthClose":0.92,"prevQuarterClose":1.085,"fiveDayClose":0.95,"twentyDayClose":1.02,"sixtyDayClose":1.045},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OCC.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OCC.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"OCC.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2608887369","title":"Orthocell Eyes Fiscal 2027 Entry Into UK, European Union Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2608887369","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608887369?lang=en_us&edition=fundamental","pubTime":"2026-02-02 07:51","pubTimestamp":1769989904,"startTime":"0","endTime":"0","summary":"Orthocell  said it plans to focus on completing launch planning for its fiscal 2027 entry into the UK and European Union markets, according to a Monday Australian bourse filing.Its total revenue for the first half of fiscal 2026 came in at AU$6.2 million, up from AU$4.2 million in the year-ago period.Orthocell estimated that it requires around 10,000 unit sales of its Remplir nerve repair product per annum in the US to reach cash breakeven, which is less than 1% of the addressable market, per the filing.The firm's shares rose 1% in early trading on Monday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","OCC.AU","BK7508"],"gpt_icon":0},{"id":"2604034649","title":"BRIEF-Orthocell Posts Quarterly Revenue Of A$3.2 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2604034649","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604034649?lang=en_us&edition=fundamental","pubTime":"2026-01-19 09:10","pubTimestamp":1768785047,"startTime":"0","endTime":"0","summary":"BRIEF-Orthocell Posts Quarterly Revenue Of A$3.2 MillionJan 19 (Reuters) - Orthocell Ltd OCC.AX:QTRLY REVENUE OF A$3.2 MILLIONFurther company coverage: OCC.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260119:nFWN3YH1FS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OCC.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2603955861","title":"Orthocell Finalizes Agreement With Biotechnology Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2603955861","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603955861?lang=en_us&edition=fundamental","pubTime":"2026-01-16 10:46","pubTimestamp":1768531607,"startTime":"0","endTime":"0","summary":"Orthocell  finalized an agreement with Marine Biomedical, increasing its equity interest to 11.7% from 1.72% for a total investment of AU$1.1 million, according to a Friday filing with the Australian bourse.The company also secured global distribution rights to PearlBone, Marine Biomedical's bone regeneration technology, as well as its future bone repair products under the deal, the filing said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7067","OCC.AU"],"gpt_icon":0},{"id":"2603951930","title":"BRIEF-Orthocell Finalises Strategic Investment In Marine Biomedica","url":"https://stock-news.laohu8.com/highlight/detail?id=2603951930","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603951930?lang=en_us&edition=fundamental","pubTime":"2026-01-16 09:24","pubTimestamp":1768526652,"startTime":"0","endTime":"0","summary":"BRIEF-Orthocell Finalises Strategic Investment In Marine BiomedicaJan 16  - Orthocell Ltd OCC.AX:ORTHOCELL FINALISES STRATEGIC INVESTMENT IN MARINE BIOMEDICACO INCREASED ITS EQUITY INTEREST IN MARINE BIOMEDICAL TO 11.7% FOR TOTAL INVESTMENT OF AU$1.05  MILLIONFurther company coverage: OCC.AX ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260116:nFWN3YG0RI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OCC.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2603780936","title":"Orthocell Ltd - Orthocell Finalises Strategic Investment in Marine Biomedica","url":"https://stock-news.laohu8.com/highlight/detail?id=2603780936","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603780936?lang=en_us&edition=fundamental","pubTime":"2026-01-16 06:03","pubTimestamp":1768514586,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260115:nFWN3YG0RI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","OCC.AU","BK7067"],"gpt_icon":0},{"id":"2603752936","title":"Orthocell Ltd - Co Increased Its Equity Interest in Marine Biomedical to 11.7% for Total Investment of AU$1.05  Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2603752936","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603752936?lang=en_us&edition=fundamental","pubTime":"2026-01-16 06:03","pubTimestamp":1768514586,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260115:nFWN3YG0RI:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OCC.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2601859763","title":"BRIEF-Orthocell Posts A$3.2 Million In Revenue For Quarter Ended 31 December","url":"https://stock-news.laohu8.com/highlight/detail?id=2601859763","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601859763?lang=en_us&edition=fundamental","pubTime":"2026-01-06 09:13","pubTimestamp":1767662035,"startTime":"0","endTime":"0","summary":"BRIEF-Orthocell Posts A$3.2 Million In Revenue For Quarter Ended 31 DecemberJan 6 (Reuters) - Orthocell Ltd OCC.AX:REVENUE A$3.2 MILLION FOR QUARTER ENDED 31 DECEMBERFurther company coverage: OCC.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nFWN3Y618G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","OCC.AU","BK7508"],"gpt_icon":0},{"id":"2601859912","title":"Orthocell Posts 45% Revenue Growth for December 2025 Quarter","url":"https://stock-news.laohu8.com/highlight/detail?id=2601859912","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601859912?lang=en_us&edition=fundamental","pubTime":"2026-01-06 09:01","pubTimestamp":1767661283,"startTime":"0","endTime":"0","summary":"Orthocell  posted revenue of AU$3.2 million for the quarter ended Dec. 31, 2025, up 45% on the previous corresponding period, according to a Tuesday filing with the Australian bourse.Revenue for the period also represents a 7% increase over the previous quarter and the seventh consecutive quarter of record revenue, the filing said.The increase was mainly due to increased market penetration, particularly Australia, as well as initial financial contributions from early Remplir nerve repair product surgical cases in the US, per the filing.Shares rose past 1% in morning trade Tuesday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","OCC.AU","BK7067"],"gpt_icon":0},{"id":"2601584738","title":"Orthocell Ltd -  Revenue a$3.2 Mln for Quarter Ended 31 December","url":"https://stock-news.laohu8.com/highlight/detail?id=2601584738","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601584738?lang=en_us&edition=fundamental","pubTime":"2026-01-06 06:34","pubTimestamp":1767652456,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nFWN3Y618G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","OCC.AU"],"gpt_icon":0},{"id":"2592928082","title":"Orthocell Sells 100 Units of Nerve Repair Product in US","url":"https://stock-news.laohu8.com/highlight/detail?id=2592928082","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592928082?lang=en_us&edition=fundamental","pubTime":"2025-12-18 10:15","pubTimestamp":1766024133,"startTime":"0","endTime":"0","summary":"Orthocell  said it sold 100 units of its Remplir nerve repair product in the US, according to a Thursday Australian bourse filing.This follows 61 active submissions to US hospital Value Analysis Committees, with 17 approvals secured ahead of schedule and additional approvals anticipated in fiscal 2026, the filing said. The first 4,000 units of Remplir have been shipped from Australia and warehoused in the US.Orthocell's shares fell past 2% in recent trading on Thursday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK7508","OCC.AU"],"gpt_icon":0},{"id":"2592607189","title":"Canaccord Genuity Starts Orthocell at Speculative Buy with AU$1.33 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2592607189","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592607189?lang=en_us&edition=fundamental","pubTime":"2025-12-17 16:41","pubTimestamp":1765960918,"startTime":"0","endTime":"0","summary":"Canaccord Genuity Starts Orthocell at Speculative Buy with AU$1.33 Price Target","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7067","OCC.AU"],"gpt_icon":0},{"id":"2591960306","title":"Orthocell Submits Application to the British Standards Institution for Approval for Commercial Distribution of Nerve Repair Product, Shares Up 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591960306","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591960306?lang=en_us&edition=fundamental","pubTime":"2025-12-15 10:24","pubTimestamp":1765765494,"startTime":"0","endTime":"0","summary":"Orthocell  submitted a regulatory application to the British Standards Institution for approval to commercially distribute its nerve repair product Remplir into the European Union and UK markets, according to a Monday Australian bourse filing.The regulatory approval for the required European Conformity  and UK Conformity Assessed  certifications is expected to be received in the September quarter of 2026.Its shares rose 3% in recent trading on Monday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OCC.AU","BK7067","BK4201","BK7508","EC"],"gpt_icon":0},{"id":"2591693065","title":"BRIEF-Orthocell Submits Regulatory Application For Commercial Distribution Of Remplir","url":"https://stock-news.laohu8.com/highlight/detail?id=2591693065","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591693065?lang=en_us&edition=fundamental","pubTime":"2025-12-15 09:24","pubTimestamp":1765761864,"startTime":"0","endTime":"0","summary":"BRIEF-Orthocell Submits Regulatory Application For Commercial Distribution Of RemplirDec 15 (Reuters) - Orthocell Ltd OCC.AX:SUBMITS REGULATORY APPLICATION FOR COMMERCIAL DISTRIBUTION OF REMPLIR INTO EU + UK NERVE REPAIR MARKETFurther company coverage: OCC.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nFWN3XI0J6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","OCC.AU"],"gpt_icon":0},{"id":"2591711662","title":"Orthocell Ltd - Submits Regulatory Application for Commercial Distribution of Remplir Into EU + UK Nerve Repair Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2591711662","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591711662?lang=en_us&edition=fundamental","pubTime":"2025-12-15 06:06","pubTimestamp":1765750003,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251214:nFWN3XI0J6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","OCC.AU"],"gpt_icon":0},{"id":"2591651666","title":"XRP price slowly forms a bullish pattern amid good Ripple news","url":"https://stock-news.laohu8.com/highlight/detail?id=2591651666","media":"cryptonews","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591651666?lang=en_us&edition=fundamental","pubTime":"2025-12-14 22:14","pubTimestamp":1765721640,"startTime":"0","endTime":"0","summary":"XRP price remains in a deep bear market after erasing billions of dollars in value in the past few months despite some notable news. This pullback may end soon amid key Ripple news and as a bullish pattern forms.XRP price has formed an inverse head-and-shoulders pattern.Ripple  token dropped to the important support at $2, down by over 40% from its highest point this year. It has lagged behind the performance of other tokens like Bitcoin and Ether.XRP price remained under pressure even after a major milestone by Ripple Labs, which received abanking charterfrom the Office of the Comptroller of the Currency  on Friday.Meanwhile, XRP price has crashed despite the ongoing ETF inflows. These funds have brought in over $950 million in new money, bringing the total assets to over $1.1 billion. This is important as Solana ETFs are yet to cross the $1 billion asset milestone despite the fact that they were launched earlier than XRP’s.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"crypto_news_highlight","url":"https://crypto.news/xrp-price-slowly-forms-a-bullish-pattern-amid-good-ripple-news/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://crypto.news/xrp-price-slowly-forms-a-bullish-pattern-amid-good-ripple-news/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"crypto_news_highlight","symbols":["XRP.USD.CC","BK7508","XRP","BK4020","OCC","OCC.AU","BK7067"],"gpt_icon":0},{"id":"2591657000","title":"Ripple CTO Shares Hilarious Moment With Chris Larsen at Key Event: Details","url":"https://stock-news.laohu8.com/highlight/detail?id=2591657000","media":"utoday","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591657000?lang=en_us&edition=fundamental","pubTime":"2025-12-13 13:50","pubTimestamp":1765605000,"startTime":"0","endTime":"0","summary":"In a recent tweet, Ripple CTO David Schwartz shares a hilarious moment with Chris Larsen, Ripple chairman and co-founder, at an event, describing it as perhaps the funniest thing that has ever happened in his time at Ripple.December continues to be a busy month for Ripple, having made key appearances at major crypto events, including Binance Blockchain Week, which was held in Dubai from Dec. 3 to 4. Ripple also participated in Fintech Abu Dhabi event, which was held from Dec. 8 to 11.Ripple also indicated its participation at the Blockchain for Europe Summit at Brussels, Belgium, held Dec. 2 to 3, and Ripple Christmas Breakfast in London, U.K., on Dec. 11.In one of such events, which had himself, Chris Larsen, employees of Ripple and its recent acquisitions in attendance, Ripple CTO David Schwartz recalls an awkward moment when a new employee from one of its recent acquisitions walked up to Larsen and asked, \"So..What do you do at Ripple?","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"utodaynews_highlight","url":"https://u.today/ripple-cto-shares-hilarious-moment-with-chris-larsen-at-key-event-details","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://u.today/ripple-cto-shares-hilarious-moment-with-chris-larsen-at-key-event-details","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"utodaynews_highlight","symbols":["BK4020","BK7508","CTO","OCC","OCC.AU","LU1066051811.HKD","XRP.USD.CC","LU1066051225.USD","BK7067","LU1066053197.SGD","LU1066051498.USD","BK4160"],"gpt_icon":0},{"id":"2591318166","title":"Ripple CEO Reacts to Bank Charter Approval, Slams Banking Lobby","url":"https://stock-news.laohu8.com/highlight/detail?id=2591318166","media":"utoday","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591318166?lang=en_us&edition=fundamental","pubTime":"2025-12-12 20:51","pubTimestamp":1765543860,"startTime":"0","endTime":"0","summary":"Ripple CEO Brad Garlinghouse hasreacted to the company receiving conditional approval from the U.S. Office of the Comptroller of the Currency  to create Ripple National Trust Bank. The top executive has described this as \"huge news.\"As reported by U.Today, the San Francisco-based enterprise blockchain firm received conditional approval alongside some other crypto firms.It is a federal bank charter, which is the same type of charter that major U.S. banks operate under.In his celebratory social media post, Garlinghouse has stressed that the stablecoin becomes a fully regulated product at both the federal and state levels.\"What are you afraid of?","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"utodaynews_highlight","url":"https://u.today/ripple-ceo-reacts-to-bank-charter-approval-slams-banking-lobby","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://u.today/ripple-ceo-reacts-to-bank-charter-approval-slams-banking-lobby","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"utodaynews_highlight","symbols":["LU1201861165.SGD","BK4100","BK4585","LU0320765489.SGD","LU0648001328.SGD","XRP.USD.CC","BK7067","LU0980610538.SGD","CHTR","LU1201861249.SGD","LU0070302665.USD","LU0130518102.USD","BK4559","APT.USD.HKCC","BK4534","LU0477156797.USD","APT.USD.CC","LU0130517989.USD","LU0648000940.SGD","LU0208291251.USD","LU0211331839.USD","LU0130102774.USD","BK4588","TON.USD.CC","OCC.AU","BK4020","LU0130103400.USD","LU0289960550.SGD","BK7508","LU0175139822.USD","LU0477156953.USD","TON.USD.HKCC","OCC"],"gpt_icon":0},{"id":"2590547762","title":"Canadian analysts project increased XRP adoption in fintech sector","url":"https://stock-news.laohu8.com/highlight/detail?id=2590547762","media":"cryptonews","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590547762?lang=en_us&edition=fundamental","pubTime":"2025-12-12 07:59","pubTimestamp":1765497540,"startTime":"0","endTime":"0","summary":"Canadian financial technology analysts have issued forecasts projecting expanded adoption of XRP in digital payment systems, according to reports circulating in cryptocurrency markets.Canadian fintech researchers are forecasting wider adoption of XRP in digital payments.Analyst Skipper_xrp noted growing XRPL ecosystem activity—including interest in the raccoon-themed RACO token—while also pointing to new U.S. regulatory clarity.The ruling allows banks to facilitate XRP trades within a regulated framework, which analysts say could boost institutional integration and strengthen XRP’s positioning.Financial institutions have continued to implement blockchain-based settlement systems, prompting several Canadian researchers to issue projections on XRP’s potential role in the sector, according to industry observers.A Canadian news article highlighted XRP as a potential leading financial technology application within the cryptocurrency sector, according to a video shared by crypto analyst Skip","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"crypto_news_highlight","url":"https://crypto.news/canadian-analysts-project-xrp-adoption-fintech-sector/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://crypto.news/canadian-analysts-project-xrp-adoption-fintech-sector/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"crypto_news_highlight","symbols":["OCC","XRP","BK4020","BK7067","BK7508","OCC.AU"],"gpt_icon":0},{"id":"2590320537","title":"Orthocell Sells Nerve Repair Product in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2590320537","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590320537?lang=en_us&edition=fundamental","pubTime":"2025-12-10 07:21","pubTimestamp":1765322485,"startTime":"0","endTime":"0","summary":"Orthocell  achieved the first commercial sales of its nerve repair product, Remplir, in Hong Kong, to pharmaceutical firm MontsMed, according to a Wednesday filing with the Australian bourse.The company expects to start selling Remplir in Canada and Thailand in the near term, the filing said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK7508","OCC.AU"],"gpt_icon":0},{"id":"2584900207","title":"Remplir™ Nerve Sparing Prostate Cancer Surgery Commercial Opportunity Gathers Momentum with ~100 Surgeries Now Performed with Multiple Surgeons Nationwide","url":"https://stock-news.laohu8.com/highlight/detail?id=2584900207","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584900207?lang=en_us&edition=fundamental","pubTime":"2025-11-20 13:52","pubTimestamp":1763617920,"startTime":"0","endTime":"0","summary":"Company to invest in    further research    to strengthen    clinical    evidence ahead of medium-term U.S. launch with no further FDA approvals needed. Adoption ofRemplir among Australian urologists is accelerating, with ~100 surgeries conducted by surgeons nationwide.This promising new application forRemplir can potentially reduce post-surgical complications from peripheral nerve injury, representing a globally significant commercial opportunity for the Company.ApplyingRemplir during prostate surgery aligns with its broader role in peripheral nerve protection and repair. In prostatectomy, surgeons are using Remplir to protect the NVB with the aim of supporting improved postoperative nerve function.The Company believes that the use ofRemplir in nerve-sparing RARP presents a significant opportunity to expand its Total Addressable Market in the U.S. from U.S.$1.6 billion to approximately U.S.$2 billion   [1]   .The Company believes that using Remplir in nerve-sparing RARP presents a sig","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/remplir-nerve-sparing-prostate-cancer-surgery-commercial-opportunity-gathers-momentum-with-100-surgeries-now-performed-with-multiple-surgeons-nationwide-302621289.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XJO.AU","BK4532","BK7067","OCC.AU","ED","BK4208","LU2346227817.USD","XAO.AU","BK4585","BK4588","UI","BK4020","XKO.AU","BK7508","LU0170899867.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":58,"code":"91000000","status":"200"}]}}